-
Novo's diabetes treatment semaglutide gets unanimous FDA backing
pharmafile
October 20, 2017
Novo Nordisk is celebrating the news that its diabetes drug semaglutide has won the favour of FDA experts, with one of the regulators advisory panels voting unanimously in favour of the drug’s approval.
-
AstraZeneca Pharma gets DCG(I) nod to market diabetes drug
expressbpd
October 19, 2017
AstraZeneca Pharma has received marketing authorisation from the Drug Controller General India DCG(I) for Xigduo XR tablets used in treatment of adults with type II diabetes in India.
-
Sanofi plans summit to tackle diabetes in 5 million Nigerian citizens
pharmafile
October 18, 2017
Sanofi Aventis Nigeria plans to put together a National Diabetes Summit to address crisis in the country as five million of the nation’s citizens currently live with the condition.
-
‘OneUp’ trek challenge held for diabetes patients
expressbpd
October 13, 2017
Sanofi India, Diabetes India and Aurangabad-based NGO ‘Udaan’ recently organised ‘OneUp’ trek for people suffering from type 1 diabetes (T1D). 23 people suffering from T1D took part in the challenge.
-
IDF and Novo Nordisk launch first-ever global survey on cardiovascular disease awareness among peopl
worldpharmanews
September 30, 2017
(IDF) has partnered with Novo Nordisk to launch the first-ever multi-country online survey investigating the level of CVD awareness and knowledge among people living with type 2 diabetes
-
Ministry of AYUSH conducts online article writing contests on prevention and management of diabetes
expressbpd
September 14, 2017
Special Secretary AYUSH gives away prizes to winners of the contest
-
Biochemical fingerprints reveal diabetes progression
europeanpharmaceuticalreview
August 23, 2017
Researchers have describe a new method to study biochemical changes that occur in the pancreas during the development of diabetes…
-
Less sleep in children relevant to higher risk of diabetes
pharmafile
August 17, 2017
A study emerging from St George’s University of London found that children who slept an hour less than the recommended amount were more likely to have an increased risk of developing type 2 diabetes.
-
Lexicon Reports Additional Positive Data from Sotagliflozin Pivotal Phase 3 Study
pharmaceutical-technology
August 16, 2017
Lexicon Pharmaceuticals announced additional positive data from the pivotal Phase 3 inTandem2 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor.
-
Testing the safety of immunotherapy in diabetes
fiercebiotech
August 10, 2017
Some researchers hope immunotherapy will make these tools obsolete in treating diabetes.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
